IO Biotech Inc. (IOBT)
0.88
-0.03 (-3.75%)
At close: Mar 05, 2025, 1:32 PM
-3.75% (1D)
| Bid | 0.88 |
| Market Cap | 57.98M |
| Revenue (ttm) | 1.11M |
| Net Income (ttm) | -90.34M |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | -0.68 |
| Forward PE | -0.74 |
| Analyst | Buy |
| Ask | 0.9 |
| Volume | 142,000 |
| Avg. Volume (20D) | 183,129 |
| Open | 0.96 |
| Previous Close | 0.91 |
| Day's Range | 0.88 - 0.96 |
| 52-Week Range | 0.66 - 1.85 |
| Beta | 0.22 |
About IOBT
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and ne...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2021
Employees 78
Stock Exchange NASDAQ
Ticker Symbol IOBT
Website https://www.iobiotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for IOBT stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 1036.36% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 months ago
+3.22%
IO Biotech share are trading higher after announce...
Unlock content with
Pro Subscription
6 months ago
IO Biotech shares are trading lower after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.
